EUVIMEDEUVIMED entdecken
Crossref

Glycemic Control Across the Menstrual Cycle in Women with Type 1 Diabetes Using the MiniMed 780G Advanced Hybrid Closed-Loop System: The 780MENS Prospective Study

Gabriela Monroy iD, María José Picón-César iD, Jorge García-Alemán, Francisco J Tinahones, José Ignacio Martínez-Montoro iD

Diabetes Technology & Therapeutics · 2025

DOI: 10.1089/dia.2024.0522 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Technology & Therapeutics, 2025. Verfasst von Gabriela Monroy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Nutrition, Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Spain. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin Infusion Systems, Blood Glucose, Insulin. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate whether the MiniMed™ 780G advanced hybrid closed-loop (AHCL) system maintains similar glycemic control across two different phases of the menstrual cycle in women with type 1 diabetes (T1D) and to analyze the system’s performance in these situations.

Methods

Continuous glucose monitoring (CGM) and insulin delivery metrics from 12 participants with T1D using the MiniMed™ 780G AHCL were analyzed throughout 3 prospectively recorded, consecutive menstrual cycles (36 cycles in total). Mixed models were used to compare the different variables between the early follicular phase and late luteal phase.

Results

A higher average glucose was found throughout the late luteal phase compared with the early follicular phase (139.5 [133.5, 145.2] vs. 131.5 [126.8, 140.2] mg/dl, respectively, P = 0.002), together with an increase in total daily insulin dose (37.2 ± 11.9 vs. 33.6 ± 12.2 IU, P < 0.001). However, similar values between phases were observed for most of the remaining CGM metrics, including time in range (83.0 [76.0, 87.5] vs. 85.0 [79.8, 89.0] %, P = 0.101).

Conclusion

Our results suggest that differences in glycemic control may be found across the menstrual cycle in women with T1D using the MiniMed™ 780G AHCL. Although higher average glucose levels may be expected in the late luteal phase, the deterioration of glycemic control during this phase may be mild with the MiniMed™ 780G AHCL, given the similarities for most of the CGM metrics with respect to the early follicular phase.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Insulin Infusion SystemsBlood GlucoseInsulinHypoglycemic AgentsGlycemic ControlMenstrual CycleHumansFemaleAdultProspective StudiesBlood Glucose Self-MonitoringYoung AdultFollicular PhaseLuteal Phase

Stichwörter der Autor:innen

MiniMed™ 780Gadvanced hybrid closed-loop systemsglycemic controlmenstrual cycletype 1 diabetes

Substanzen

Blood GlucoseInsulinHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Endocrinology and Nutrition, Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Spain.
  • Fundació de Recerca Sant Joan de Déu, Barcelona, Spain.
  • Institut de Recerca Biomèdica de Lleida Fundació Dr. Pifarré, IRBLleida, Spain.
  • Department of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, Málaga, Spain.
  • Instituto de Investigación Biomédica de Málaga (IBIMA)- Plataforma BIONAND, Málaga, Spain.
  • Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y la Nutrición (CIBERObn), Instituto de Salud Carlos III, Madrid, Spain.

ORCID-Profile: Gabriela Monroy, María José Picón-César, José Ignacio Martínez-Montoro

Zitieren

APA

Monroy, G., Picón-César, M. J., García-Alemán, J., Tinahones, F. J., & Martínez-Montoro, J. I. (2025). Glycemic Control Across the Menstrual Cycle in Women with Type 1 Diabetes Using the MiniMed 780G Advanced Hybrid Closed-Loop System: The 780MENS Prospective Study. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2024.0522

Vancouver

Monroy G, Picón-César MJ, García-Alemán J, Tinahones FJ, Martínez-Montoro JI. Glycemic Control Across the Menstrual Cycle in Women with Type 1 Diabetes Using the MiniMed 780G Advanced Hybrid Closed-Loop System: The 780MENS Prospective Study. Diabetes Technology & Therapeutics. 2025. doi:10.1089/dia.2024.0522

BibTeX
@article{Monroy2025,
  author = {Monroy, Gabriela and Picón-César, María José and García-Alemán, Jorge and Tinahones, Francisco J and Martínez-Montoro, José Ignacio},
  title = {Glycemic Control Across the Menstrual Cycle in Women with Type 1 Diabetes Using the MiniMed 780G Advanced Hybrid Closed-Loop System: The 780MENS Prospective Study},
  journal = {Diabetes Technology & Therapeutics},
  year = {2025},
  doi = {10.1089/dia.2024.0522}
}
Kostenlos starten →